Al18F-HER2-BCH PET/CT to Predict Response in Breast Patients Treated With Neoadjuvant Therapy
Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with neoadjuvant therapy
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Aged ≥18 years old; ECOG 0 or 1;
• Patients with newly diagnosis HER2 positive or suspicious positive tumors;
• Receives neoadjuvant therapy
• Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
• Life expectancy \> 3 months -
Locations
Other Locations
China
Peking University Cancer Hospital & Institute
RECRUITING
Beijing
Contact Information
Primary
Xiaoyi Guo, PhD
15833916752@163.com
010-88196495
Backup
Yannan Yuan
gcp_yuanyn@bjcancer.org
01088197730
Time Frame
Start Date: 2025-01-01
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 50
Treatments
Experimental: HER2 expression of PET imaging
Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast cancer patients treated with neoadjuvant therapy
Related Therapeutic Areas
Sponsors
Collaborators: North Sichuan Medical College, The Affiliated Hospital of Qingdao University
Leads: Peking University Cancer Hospital & Institute